Primary double invasive cervical carcinoma, squamous cell carcinoma and adenocarcinoma - case report

A case of 56-year old women with double primary invasive cervical carcinoma, squamous cell carcinoma and endometrioid adenocarcinoma is presented. The patient was subjected to radical abdominal hysterectomy with pelvic and paraaortic lymphadenectomy. Surgery was followed by radiotherapy. Since the treatment the patient has been doing well and is free of any signs of relapse of the disease.

Cervical carcinoma; Squamous cell carcinoma; Adenocarcinoma

[1] Zheng T., Holford T.R., Ma Z., Chen Y., Liu W., Ward B.A. et al.: “The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon”. Int. J. Epidemiol., 1996, 25, 252.

[2] Bergstrom R., Sparen P., Adami H.O.: “Trends in cancer of the cervix uteri in Sweden following cytological screening”. Br. J. Cancer, 1999, 81, 159.

[3] Ferlay J., Black R.J., Pisani P, Valdivieso M.T., Parkin D.M.: “Eucan 90: Cancer in the European Union”. In: IARC Cancer Base No I. International Agency for Research on Cancer, Lyon, France, 1996.

[4] Parker S.L., Tong T., Bolden S., Wingo P.A.: “Cancer statistics”, 1996. CA. Cancer J. Clin., 1996, 46, 5.

[5] Lacey J.V., Swanson C.A., Brinton L.A. et al.: “Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix”. Cancer, 2003, 98, 814.

[6] Green J., Berrington de Gonzalez A., Sweetland S., Beral V., Chilvers C., Crossley B. et al.: “Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National case-control study of cervical cancer”. Br. J. Cancer, 2003, 89, 2078.

[7] Altekruse S.F., Lacey J.V., Brinton L.A., Gravitt P.E., Silverberg S.G., Barnes W.A.: “Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States”. Am. J. Obstet. Gynecol., 2003, 188, 657.

[8] Eifel P.J., Berek J.S., Thigpen J.T.: “Cancer of the cervix, vagina and vulva”. In: De Vita V.T., Hellman S., Rosenberg S.A., (eds.) “Cancer: Principles and Practice of Oncology”, 6th edition, Philadelphia, JB Lippincott, Williams and Wilkins, 2001, 1526.

[9] Shinohara S., Ochi T., Miyazaki T., Fujii T., Kawamura M., Mochizuki T., Ito M.: “Histopathological prognostic factors in patients with cervical cancer treated with radical hysterectomy and postoperative radiotherapy”. Int. J. Clin. Oncol., 2004, 9, 503.

[10] Kamura T., Tsukamoto N., Tsuruchi N., Saito T., Matsuyama T., Akazawa K., Nakano H.: “Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy”. Cancer, 1992, 69, 181.

[11] Piura B., Rabinovich A., Friger M.: “Surgical pathologic factors in patients with early-stage cervical carcinoma treated with radical hysterectomy and pelvic lymph node dissection: association with administration of adjuvant radiotherapy and effect on survival”. Eur. J. Gynaecol. Oncol., 2006, 27, 573.

[12] Hopkins M.P., Morley G.W.: “A comparison of adenocarcinoma and squamous cell carcinoma of the cervix”. Obstet. Gynecol., 1991, 77, 912.

[13] FIGO Committee on Gynecologic Oncology: Staging classifications and clinical practice guidelines of gynecologic cancers. Int. J. Gynecol. Obstet., 2000, 70, 207.

[14] Smith H.O., Tiffany M.F., Qualls C.R., Key C.R.: “The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study”. Gynecol. Oncol., 2000, 78, 97.

[15] Vizcaino A.P., Moreno V., Bosch F.X., Munoz N., Barros-Dios X.M., Parkin D.M.: “International trends in the incidence of cervical cancer. I. Adenocarcinoma and adenosquamous cell carcinomas”. Int. J. Cancer, 1998, 75, 536.

[16] Anttila T., Saikku P., Koskela P., Bloigu A., Dillner J., Ikäheimo I. et al.: “Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma”. JAMA, 2001, 285, 47.

[17] Pettersson F.: “Annual report on the results of treatment in gynecological cancer”. Radiumhemmet, Stockholm, Sweden. International Federation of Gynecology and Obstetrics (FIGO), 1994, 132.

[18] Hsich C.Y., Wu C.C., Chen T.M., Chen C.A., Chen C.L., Wang J.F. et al.: “Clinical significance of intratumoral blood flow in cervical carcinoma assessed by color Doppler ultrasound”. Cancer, 1995, 75, 2518.

[19] Bender D.P., Sorosky J.I., Buller R.E., Sood A.K.: “Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma”. Am. J. Obstet. Gynecol., 2003, 189, 113.

[20] Papp Z., Csapo’ Zs., Hupuczi P., Mayer A’.: “Nerve-sparing radical hysterectomy for Stage IA2-IIB cervical cancer: 5-year survival of 501 consecutive cases”. Eur. J. Gynaecol. Oncol., 2006, 27, 553.